[
  {
    "ts": "2025-08-04T20:30:00+00:00",
    "headline": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)",
    "summary": "LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato",
    "url": "https://finance.yahoo.com/news/onco360-selected-specialty-pharmacy-partner-203000940.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0873c3d6-945b-3baf-90a2-2663da19d855",
      "content": {
        "id": "0873c3d6-945b-3baf-90a2-2663da19d855",
        "contentType": "STORY",
        "title": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)",
        "description": "",
        "summary": "LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato",
        "pubDate": "2025-08-04T20:30:00Z",
        "displayTime": "2025-08-04T20:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/9a7e5e5c56464a2f4a38a2c29cd6fe09",
          "originalWidth": 4320,
          "originalHeight": 1440,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ksNto5s_pnXJIcSZNqCcJA--~B/aD0xNDQwO3c9NDMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/9a7e5e5c56464a2f4a38a2c29cd6fe09.cf.webp",
              "width": 4320,
              "height": 1440,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y5VpmHpi5AiD3l2WlEle9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9a7e5e5c56464a2f4a38a2c29cd6fe09.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/onco360-selected-specialty-pharmacy-partner-203000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/onco360-selected-specialty-pharmacy-partner-203000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T11:36:37+00:00",
    "headline": "Manufacturing issues at Novo facility disrupt Regeneron drug review",
    "summary": "Issues were picked up during an FDA inspection of Novo Nordisk's mammoth filling plant.",
    "url": "https://www.pharmaceutical-technology.com/news/manufacturing-issues-at-novo-facility-disrupt-regeneron-drug-review/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "12531104-70a4-35e2-b932-f65cd7a37ee9",
      "content": {
        "id": "12531104-70a4-35e2-b932-f65cd7a37ee9",
        "contentType": "STORY",
        "title": "Manufacturing issues at Novo facility disrupt Regeneron drug review",
        "description": "",
        "summary": "Issues were picked up during an FDA inspection of Novo Nordisk's mammoth filling plant.",
        "pubDate": "2025-08-04T11:36:37Z",
        "displayTime": "2025-08-04T11:36:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/3cb0d6270dc527d1ea7d95da86b116e8",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Regeneron’s antibody acts by connecting BCMA on MM cells with T cells that express CD3. Credit: lev radin/Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V8WjMue9I5V_KL39v9D8MQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/3cb0d6270dc527d1ea7d95da86b116e8.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.VB0vg5vaB7nYPRpC6awMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/3cb0d6270dc527d1ea7d95da86b116e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/manufacturing-issues-at-novo-facility-disrupt-regeneron-drug-review/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/manufacturing-issues-novo-facility-disrupt-113637316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]